Neuren launches $50m share buy-back
Neuren Pharmaceuticals (ASX:NEU), an Australian biotech focused on developing treatments for neurological disorders, has announced a substantial on-market share buy-back program. The company intends to repurchase up to A$50 million in shares, citing stable cash inflow from sales of its Rett syndrome drug, DAYBUE, in the United States as a driving factor. The program allows […]
Neuren launches $50m share buy-back Read More »